Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter,...

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Richter transformation (RT) is a serious complication of chronic lymphocytic leukemia (CLL) with limited treatment options and poor prognosis.
• The efficacy and safety of anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for RT have not been well-established.

Purpose of the Study:

• To evaluate the clinical efficacy and safety of anti-CD19 CAR-T therapy in patients with Richter transformation.
• To assess progression-free survival (PFS) and overall survival (OS) following CAR-T therapy for RT.

Main Methods:

• An international multicenter retrospective study was conducted involving patients with RT who received CAR-T therapy.
• Descriptive statistics and modeling analyses were used to summarize patient characteristics and assess associations with PFS and OS.
• PFS and OS were calculated from the date of CAR-T infusion.

Main Results:

• Sixty-nine patients with RT received CAR-T therapy, with a median of four prior lines of therapy.
• The overall response rate was 63%, with 46% achieving complete response (CR).
• Median PFS was 4.7 months, 2-year PFS was 29%, median OS was 8.5 months, and 2-year OS was 38%.

Conclusions:

• CAR-T therapy demonstrates clinical efficacy in patients with Richter transformation.
• CAR-T therapy offers a potential new treatment avenue for patients with RT, a condition with historically poor outcomes.